Nurix Therapeutics, Inc. (NRIX) stock
NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026Score 15/3073% below fair value
$15.48−0.12 (-0.77%)
Close on Nov 13, 2026Market cap $1.69BP/E 6.7Yield 0.00%
Earnings
Nurix Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Jan 27, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$673.10M
+8420.3% on a year earlier
EPS, Q3 FY2026
$4.73
-$1.03 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Nurix Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Nov 30, 2026 | Jan 27, 2027Expected | – | – | – | – |
| Q3 FY2026ended Aug 31, 2026 | Oct 13, 2026before the open | $673.10M | +8420.3% | $4.73 | Release |
| Q2 FY2026ended May 31, 2026 | Jul 9, 2026after the close | $9.00M | -79.6% | – | Release |
| Q1 FY2026ended Feb 28, 2026 | Apr 8, 2026before the open | $6.30M | -65.9% | – | Release |
| Q4 FY2025ended Nov 30, 2025 | Jan 28, 2026after the close | $13.60M | +2.3% | -$0.82 | Release |
| Q3 FY2025ended Aug 31, 2025 | Oct 9, 2025after the close | $7.90M | -37.3% | -$1.03 | Release |
| Q2 FY2025ended May 31, 2025 | Jul 9, 2025after the close | $44.10M | +264.5% | -$0.52 | Release |
| Q1 FY2025ended Feb 28, 2025 | Apr 8, 2025after the close | $18.50M | +11.4% | -$0.67 | Release |
| Q4 FY2024ended Nov 30, 2024 | Jan 28, 2025after the close | $13.30M | -12.5% | -$0.75 | Release |
| Q3 FY2024ended Aug 31, 2024 | Oct 11, 2024after the close | $12.60M | -31.9% | -$0.67 | Release |
| Q2 FY2024ended May 31, 2024 | Jul 11, 2024after the close | $12.10M | -60.6% | -$0.71 | Release |
| Q1 FY2024ended Feb 29, 2024 | Apr 10, 2024before the open | $16.60M | +30.7% | -$0.76 | Release |
| Q4 FY2023ended Nov 30, 2023 | Feb 15, 2024after the close | $15.20M | +123.5% | -$0.77 | Release |
| Q3 FY2023ended Aug 31, 2023 | Oct 12, 2023after the close | $18.50M | +71.3% | -$0.68 | Release |
| Q2 FY2023ended May 31, 2023 | Jul 13, 2023after the close | $30.70M | +169.3% | -$0.45 | Release |
| Q1 FY2023ended Feb 28, 2023 | Apr 13, 2023after the close | $12.70M | +32.3% | -$0.75 | Release |
| Q4 FY2022ended Nov 30, 2022 | Feb 9, 2023after the close | $6.80M | -8.1% | -$0.87 | Release |
| Q3 FY2022ended Aug 31, 2022 | Oct 6, 2022after the close | $10.80M | – | -$0.90 | Release |
| Q2 FY2022ended May 31, 2022 | Jul 7, 2022after the close | $11.40M | – | -$1.01 | Release |
| Q1 FY2022ended Feb 28, 2022 | Apr 7, 2022after the close | $9.60M | – | -$0.95 | Release |
| Q4 FY2021ended Nov 30, 2021 | Jan 27, 2022after the close | $7.40M | – | -$0.85 | Release |
| Q3 FY2021ended Aug 31, 2021 | Oct 14, 2021after the close | – | – | – | Release |
| Q2 FY2021ended May 31, 2021 | Jul 13, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Feb 28, 2021 | Apr 13, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Nov 30, 2020 | Feb 16, 2021after the close | – | – | – | Filing |
| Q3 FY2020ended Aug 31, 2020 | Oct 14, 2020after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Nurix Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Nurix Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Nurix Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Update
- Results
- Results
- Update
- Update
- Update
- Update
- Update
- News
- Update
- Update
See a number that looks wrong?